Please provide your email address to receive an email when new articles are posted on . AF recurrence after pulsed field ablation was comparable vs. after radiofrequency ablation. There were fewer ...

Six-month outcomes from the Ventricular Catheter Ablation Study, the first-in-human evaluation of its FieldForce Ablation System for ventricular tachycardia (VT), have been published in Circulation.

Boston Scientific leads the pulsed field ablation (PFA) technology market to treat atrial fibrillation (Afib). But it is by no means alone in its commitment to this relatively new way to treat some ...

Emerging pulsed field ablation systems have made a major impact in the treatment of atrial fibrillation, with major medtechs receiving international approvals in the past year as newcomers wait in the ...

First-line treatment with pulsed field ablation (PFA) reduced the risk of recurrence of atrial arrhythmia among patients with persistent atrial fibrillation (Afib), the randomized AVANT GUARD trial ...

SAN DIEGO — Building on the success of a growing number of devices employing pulsed field ablation to control treatment-resistant paroxysmal atrial fibrillation (AF), a new spherical device produced ...

Pulsed field ablation did not have superior efficacy to radiofrequency ablation in patients with drug-resistant paroxysmal (intermittent) atrial fibrillation, according to results from a late-breaking ...

Guidelines recommend a trial of antiarrhythmic drugs before catheter ablation for persistent atrial fibrillation. Whether pulsed field ablation (PFA) may be a preferred initial treatment is unclear.

Please provide your email address to receive an email when new articles are posted on . A novel pulsed field ablation technology successfully treated most patients with paroxysmal AF. The rate of ...

The future of pulsed field ablation (PFA) technology could go in the direction of high-voltage nanosecond energy bursts, according to early results of a novel device. With CellFX nsPFA-360 PFA for ...

IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced the launch of VARIPULSE Pro in Europe following CE Mark approval, further advancing its pulsed field ablation (PFA) ...